Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Implementation of SARS-CoV-2 monoclonal antibody infusion sites at three medical centers in the United States: Strengths and challenges assessment to inform COVID-19 pandemic and future public health emergency use

View ORCID ProfileAnastasia S. Lambrou, John T. Redd, Miles A. Stewart, View ORCID ProfileKaitlin Rainwater-Lovett, Jonathan K. Thornhill, Lynn Hayes, Gina Smith, George M. Thorp, Christian Tomaszewski, Adolphe Edward, Natalia Elías Calles, Mark Amox, Steven Merta, Tiffany Pfundt, Victoria Callahan, Adam Tewell, Helga Scharf-Bell, Samuel Imbriale, Jeffrey D. Freeman, Michael Anderson, Robert P. Kadlec
doi: https://doi.org/10.1101/2021.04.05.21254707
Anastasia S. Lambrou
1Office of the Assistant Secretary for Preparedness and Response, U. S. Department of Health and Human Services, Washington, DC, U.S.
2Johns Hopkins University Applied Physics Laboratory, Laurel, Maryland, U.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anastasia S. Lambrou
  • For correspondence: Anastasia.Lambrou@hhs.gov
John T. Redd
1Office of the Assistant Secretary for Preparedness and Response, U. S. Department of Health and Human Services, Washington, DC, U.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miles A. Stewart
1Office of the Assistant Secretary for Preparedness and Response, U. S. Department of Health and Human Services, Washington, DC, U.S.
2Johns Hopkins University Applied Physics Laboratory, Laurel, Maryland, U.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kaitlin Rainwater-Lovett
1Office of the Assistant Secretary for Preparedness and Response, U. S. Department of Health and Human Services, Washington, DC, U.S.
2Johns Hopkins University Applied Physics Laboratory, Laurel, Maryland, U.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kaitlin Rainwater-Lovett
Jonathan K. Thornhill
1Office of the Assistant Secretary for Preparedness and Response, U. S. Department of Health and Human Services, Washington, DC, U.S.
2Johns Hopkins University Applied Physics Laboratory, Laurel, Maryland, U.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lynn Hayes
1Office of the Assistant Secretary for Preparedness and Response, U. S. Department of Health and Human Services, Washington, DC, U.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gina Smith
1Office of the Assistant Secretary for Preparedness and Response, U. S. Department of Health and Human Services, Washington, DC, U.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George M. Thorp
1Office of the Assistant Secretary for Preparedness and Response, U. S. Department of Health and Human Services, Washington, DC, U.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Tomaszewski
3El Centro Regional Medical Center, El Centro, CA, U.S.
4UC San Diego Health, San Diego, CA, U.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adolphe Edward
3El Centro Regional Medical Center, El Centro, CA, U.S.
4UC San Diego Health, San Diego, CA, U.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natalia Elías Calles
5TMC HealthCare, Tucson, AZ, U.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Amox
6Sunrise Hospital and Medical Center, Las Vegas, NV, U.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Merta
6Sunrise Hospital and Medical Center, Las Vegas, NV, U.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tiffany Pfundt
1Office of the Assistant Secretary for Preparedness and Response, U. S. Department of Health and Human Services, Washington, DC, U.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Victoria Callahan
1Office of the Assistant Secretary for Preparedness and Response, U. S. Department of Health and Human Services, Washington, DC, U.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adam Tewell
1Office of the Assistant Secretary for Preparedness and Response, U. S. Department of Health and Human Services, Washington, DC, U.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helga Scharf-Bell
1Office of the Assistant Secretary for Preparedness and Response, U. S. Department of Health and Human Services, Washington, DC, U.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuel Imbriale
1Office of the Assistant Secretary for Preparedness and Response, U. S. Department of Health and Human Services, Washington, DC, U.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey D. Freeman
1Office of the Assistant Secretary for Preparedness and Response, U. S. Department of Health and Human Services, Washington, DC, U.S.
2Johns Hopkins University Applied Physics Laboratory, Laurel, Maryland, U.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Anderson
1Office of the Assistant Secretary for Preparedness and Response, U. S. Department of Health and Human Services, Washington, DC, U.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert P. Kadlec
1Office of the Assistant Secretary for Preparedness and Response, U. S. Department of Health and Human Services, Washington, DC, U.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background The COVID-19 pandemic caught the globe unprepared without targeted medical countermeasures, such as therapeutics, to target the emerging SARS-CoV-2 virus. However, in recent months multiple monoclonal antibody therapeutics to treat COVID-19 have been authorized by the U.S. Food and Drug Administration (FDA) under Emergency Use Authorization (EUA). Despite these authorizations and promising clinical trial efficacy results, monoclonal antibody therapies are currently underutilized as a treatment for COVID-19 across the U.S. Many barriers exist when deploying a new infused therapeutic during an ongoing pandemic with limited resources and staffing, and it is critical to better understand the process and site requirements of incorporating monoclonal antibody infusions into pandemic response activities.

Methods We examined the monoclonal antibody infusion site process components, resources, and requirements during the COVID-19 pandemic using data from three initial infusion sites at medical centers in the U.S. supported by the National Disaster Medical System. A descriptive analysis was conducted using process assessment metrics to inform recommendations to strengthen monoclonal antibody infusion site implementation.

Results The monoclonal antibody infusion sites varied in physical environment and staffing models due to state polices, infection control mechanisms, and underlying medical system structure, but exhibited a common process workflow. Sites operationalized an infusion process staffing model with at least two nurses per ten infusion patients. Monoclonal antibody implementation success factors included tailoring the infusion process to the patient community, strong engagement with local medical providers, batch preparing the therapy before patient arrival, placing the infusion center in proximity to emergency services, and creating procedures resilient to EUA changes. Infusion process challenges stemmed from confirming patient SARS-CoV-2 positivity, strained staff, scheduling needs, and coordination with the pharmacy for therapy preparation.

Conclusions Infusion site processes are most effective when integrated into the pre-existing pandemic response ecosystems and can be implemented with limited staff and physical resources. As the pandemic and policy tools such as EUAs evolve, monoclonal antibody infusion processes must also remain adaptable, as practice changes directly affect resources, staffing, timing, and workflows. Future use may be aided by incorporating innovative emergency deployment techniques, such as vehicle and home-based therapy administration, and by developing drug delivery mechanisms that alleviate the need for observed intravenous infusions by medically-accredited staff.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was supported by the US Department of Health and Human Services (HHS), Office of the Assistant Secretary for Preparedness and Response (ASPR) through HHS/ASPR contract #: 75A50121C00003. None of the authors received any payments or influence from a third-party source for the work presented.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This clinical support activity was conducted as part of the ASPR public health response to the COVID-19 pandemic and at the request of the host institutions. Under HHS Office of Health Research Protection guidelines, it was judged a non-research COVID-19 response activity. The Johns Hopkins University Applied Physics Laboratory (JHU/APL) Environmental Health Services Board and all three medical sites also deemed this work non-human subjects research exempt from institution review board approval.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data was collected as part of the ASPR public health response to the COVID-19 pandemic and is not publicly available.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted April 06, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Implementation of SARS-CoV-2 monoclonal antibody infusion sites at three medical centers in the United States: Strengths and challenges assessment to inform COVID-19 pandemic and future public health emergency use
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Implementation of SARS-CoV-2 monoclonal antibody infusion sites at three medical centers in the United States: Strengths and challenges assessment to inform COVID-19 pandemic and future public health emergency use
Anastasia S. Lambrou, John T. Redd, Miles A. Stewart, Kaitlin Rainwater-Lovett, Jonathan K. Thornhill, Lynn Hayes, Gina Smith, George M. Thorp, Christian Tomaszewski, Adolphe Edward, Natalia Elías Calles, Mark Amox, Steven Merta, Tiffany Pfundt, Victoria Callahan, Adam Tewell, Helga Scharf-Bell, Samuel Imbriale, Jeffrey D. Freeman, Michael Anderson, Robert P. Kadlec
medRxiv 2021.04.05.21254707; doi: https://doi.org/10.1101/2021.04.05.21254707
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Implementation of SARS-CoV-2 monoclonal antibody infusion sites at three medical centers in the United States: Strengths and challenges assessment to inform COVID-19 pandemic and future public health emergency use
Anastasia S. Lambrou, John T. Redd, Miles A. Stewart, Kaitlin Rainwater-Lovett, Jonathan K. Thornhill, Lynn Hayes, Gina Smith, George M. Thorp, Christian Tomaszewski, Adolphe Edward, Natalia Elías Calles, Mark Amox, Steven Merta, Tiffany Pfundt, Victoria Callahan, Adam Tewell, Helga Scharf-Bell, Samuel Imbriale, Jeffrey D. Freeman, Michael Anderson, Robert P. Kadlec
medRxiv 2021.04.05.21254707; doi: https://doi.org/10.1101/2021.04.05.21254707

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Health Systems and Quality Improvement
Subject Areas
All Articles
  • Addiction Medicine (76)
  • Allergy and Immunology (198)
  • Anesthesia (54)
  • Cardiovascular Medicine (492)
  • Dentistry and Oral Medicine (90)
  • Dermatology (56)
  • Emergency Medicine (169)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (212)
  • Epidemiology (5706)
  • Forensic Medicine (3)
  • Gastroenterology (217)
  • Genetic and Genomic Medicine (870)
  • Geriatric Medicine (88)
  • Health Economics (232)
  • Health Informatics (763)
  • Health Policy (394)
  • Health Systems and Quality Improvement (254)
  • Hematology (105)
  • HIV/AIDS (182)
  • Infectious Diseases (except HIV/AIDS) (6497)
  • Intensive Care and Critical Care Medicine (391)
  • Medical Education (118)
  • Medical Ethics (28)
  • Nephrology (93)
  • Neurology (850)
  • Nursing (44)
  • Nutrition (141)
  • Obstetrics and Gynecology (163)
  • Occupational and Environmental Health (263)
  • Oncology (515)
  • Ophthalmology (163)
  • Orthopedics (44)
  • Otolaryngology (107)
  • Pain Medicine (48)
  • Palliative Medicine (21)
  • Pathology (149)
  • Pediatrics (251)
  • Pharmacology and Therapeutics (147)
  • Primary Care Research (114)
  • Psychiatry and Clinical Psychology (972)
  • Public and Global Health (2237)
  • Radiology and Imaging (377)
  • Rehabilitation Medicine and Physical Therapy (174)
  • Respiratory Medicine (313)
  • Rheumatology (109)
  • Sexual and Reproductive Health (81)
  • Sports Medicine (82)
  • Surgery (118)
  • Toxicology (25)
  • Transplantation (34)
  • Urology (42)